Ophthalmic medications represent a disproportionate 15% of all active drug shortages in the United States.
The median duration of an ophthalmic drug shortage is 326 days, significantly exceeding the 298-day median observed for non-ophthalmic medications (p=0.023).
Patent protection serves as a critical buffer; off-patent ophthalmic drugs experience shortages nearly twice as long as patent-protected counterparts (359 vs. 184 days).
Anti-infective agents (35%) and steroids (26%) constitute the majority of ophthalmic supply disruptions, posing severe risks to vision preservation.
Background
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.